These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 8405374)

  • 21. Binding of soluble immune complexes to human lymphoblastoid cells. I. Characterization of receptors for IgG Fc and complement and description of the binding mechanism.
    Theofilopoulos AN; Dixon FJ; Bokisch VA
    J Exp Med; 1974 Oct; 140(4):877-94. PubMed ID: 4139225
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epstein Barr virus/complement C3d receptor is an interferon alpha receptor.
    Delcayre AX; Salas F; Mathur S; Kovats K; Lotz M; Lernhardt W
    EMBO J; 1991 Apr; 10(4):919-26. PubMed ID: 1849076
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the binding of C3S and C3F to complement receptors types 1, 2, and 3.
    Bartók I; Walport MJ
    J Immunol; 1995 May; 154(10):5367-75. PubMed ID: 7730637
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Binding of C3 and C3dg to the CR2 complement receptor induces growth of an Epstein-Barr virus-positive human B cell line.
    Hatzfeld A; Fischer E; Levesque JP; Perrin R; Hatzfeld J; Kazatchkine MD
    J Immunol; 1988 Jan; 140(1):170-5. PubMed ID: 2826586
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Solution structure of TT30, a novel complement therapeutic agent, provides insight into its joint binding to complement C3b and C3d.
    Li K; Gor J; Holers VM; Storek MJ; Perkins SJ
    J Mol Biol; 2012 May; 418(3-4):248-63. PubMed ID: 22387467
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activation of human platelets through gp140, the C3d/EBV receptor (CR2).
    Nunez D; Charriaut-Marlangue C; Barel M; Benveniste J; Frade R
    Eur J Immunol; 1987 Apr; 17(4):515-20. PubMed ID: 2952514
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Events related to Epstein-Barr virus binding and superinfection of Raji cells.
    Barile G; Di Certo MG; Cirone M; Frati L; Pontieri GM; Faggioni A; Di Renzo L
    Intervirology; 1994; 37(5):245-51. PubMed ID: 7698879
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of a spontaneously shed fragment of B cell complement receptor type two (CR2) containing the C3d-binding site.
    Myones BL; Ross GD
    Complement; 1987; 4(2):87-98. PubMed ID: 3497773
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutational analyses reveal that the staphylococcal immune evasion molecule Sbi and complement receptor 2 (CR2) share overlapping contact residues on C3d: implications for the controversy regarding the CR2/C3d cocrystal structure.
    Isenman DE; Leung E; Mackay JD; Bagby S; van den Elsen JM
    J Immunol; 2010 Feb; 184(4):1946-55. PubMed ID: 20083651
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mapping of the C3d receptor (CR2)-binding site and a neoantigenic site in the C3d domain of the third component of complement.
    Lambris JD; Ganu VS; Hirani S; Müller-Eberhard HJ
    Proc Natl Acad Sci U S A; 1985 Jun; 82(12):4235-9. PubMed ID: 2408276
    [TBL] [Abstract][Full Text] [Related]  

  • 31. gp140, a C3b-binding membrane component of lymphocytes, is the B cell C3dg/C3d receptor (CR2) and is distinct from the neutrophil C3dg receptor (CR4).
    Frade R; Myones BL; Barel M; Krikorian L; Charriaut C; Ross GD
    Eur J Immunol; 1985 Dec; 15(12):1192-7. PubMed ID: 3878789
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interaction of iC3b with recombinant isotypic and chimeric forms of CR2.
    Kalli KR; Ahearn JM; Fearon DT
    J Immunol; 1991 Jul; 147(2):590-4. PubMed ID: 1830068
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure and functions of gp 140, the C3d/EBV receptor (CR2) of human B lymphocytes.
    Frade R
    Mol Immunol; 1986 Nov; 23(11):1249-53. PubMed ID: 2950318
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Herpes simplex virus glycoprotein C: molecular mimicry of complement regulatory proteins by a viral protein.
    Huemer HP; Wang Y; Garred P; Koistinen V; Oppermann S
    Immunology; 1993 Aug; 79(4):639-47. PubMed ID: 8406590
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparative study of normal B cells and the EBV-positive Burkitt's lymphoma cell line, Raji, as activators of the complement system.
    Marquart HV; Olesen EH; Johnson AA; Damgaard G; Leslie RG
    Scand J Immunol; 1997 Sep; 46(3):246-53. PubMed ID: 9315112
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A revised mechanism for the activation of complement C3 to C3b: a molecular explanation of a disease-associated polymorphism.
    Rodriguez E; Nan R; Li K; Gor J; Perkins SJ
    J Biol Chem; 2015 Jan; 290(4):2334-50. PubMed ID: 25488663
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of specific binding sites on Candida with functional and antigenic characteristics of human complement receptors.
    Edwards JE; Gaither TA; O'Shea JJ; Rotrosen D; Lawley TJ; Wright SA; Frank MM; Green I
    J Immunol; 1986 Dec; 137(11):3577-83. PubMed ID: 2946764
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of the membrane receptor for the complement fragment C3d by means of a monoclonal antibody.
    Iida K; Nadler L; Nussenzweig V
    J Exp Med; 1983 Oct; 158(4):1021-33. PubMed ID: 6225820
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of CR1 and CR2 complement receptors following Epstein-Barr virus infection of Burkitt's lymphoma cell lines.
    Cohen JH; Fischer E; Kazatchkine MD; Lenoir GM; Lefevre-Delvincourt C; Revillard JP
    Scand J Immunol; 1987 Jun; 25(6):587-98. PubMed ID: 3037684
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cleavage of the complement system C3 component by HIV-1 proteinase.
    Kisselev AF; Mentele R; von der Helm K
    Biol Chem; 1997 May; 378(5):439-42. PubMed ID: 9191031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.